Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for a novel monoclonal antibody.
This break into clinical development is the result of a collaboration between MorphoSys and Galapagos – two European billion-euro Biotechs.
The phase I trial will evaluate the safety of MOR106 in at least 56 healthy volunteers, and will be conducted in Belgium. As a secondary objective, it will also characterize how the drug performs in the human body (pharmacokinetics) and possible immunogenicity (that could lead to side effects).
The topline results of the complete study are expected in the second half of 2017. As previously agreed in the partnership, Galapagos and MorphoSys will equally share the research and development costs,